Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 102.01M P/E - EPS this Y 30.80% Ern Qtrly Grth -
Income -102.85M Forward P/E -0.82 EPS next Y -2.20% 50D Avg Chg -2.00%
Sales 8.41M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 0.45 EPS next 5Y - 52W High Chg -69.00%
Recommedations 2.00 Quick Ratio 8.21 Shares Outstanding 60.29M 52W Low Chg 47.00%
Insider Own 26.90% ROA -28.28% Shares Float 42.92M Beta 1.88
Inst Own 34.35% ROE -63.00% Shares Shorted/Prior 748.44K/704.49K Price 1.77
Gross Margin 100.00% Profit Margin - Avg. Volume 334,861 Target Price 4.13
Oper. Margin -649.00% Earnings Date Nov 11 Volume 204,128 Change -1.12%
About Kronos Bio, Inc.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc. News
11/16/24 Kronos Bio Third Quarter 2024 Earnings: Beats Expectations
11/14/24 Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
11/14/24 Kronos mulls ‘strategic alternatives’ after axing cancer drug development
11/13/24 Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
11/13/24 Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
11/05/24 Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
10/23/24 Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
10/09/24 Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
10/07/24 Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
09/25/24 Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
09/23/24 Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
09/10/24 After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
09/03/24 Kronos Bio Announces Participation in Medical and Investor Conferences in September
08/22/24 After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
08/11/24 Kronos Bio Second Quarter 2024 Earnings: Beats Expectations
08/08/24 Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update
08/08/24 CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
08/06/24 Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?
07/23/24 Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
06/20/24 Shareholders May Be More Conservative With Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For Now
KRON Chatroom

User Image GPS_OS_21_vs_SOC_5 Posted - 2 days ago

$SLS this $90M Equity is Now worth Billions, the Share Price just doesn't reflect it yet. SLS009, the secondary asset here, ASH publication Confirms 100% CR Rates, 100% complete remission, for end stage dying ASXL1+ AML Patients. Dr Zeidner running the 009 trial, as well as the $SNDX Revumenib trials, was clear all 009 Needs is 25% or Better for FDA Approval - it's coming in at 100%. SLS is the most sure thing investment you will find in the market. 13,400 ASXL1+ AML Diagnoses Each year 17,400 MDS ( AML precursor ) $KRON

User Image GPS_OS_21_vs_SOC_5 Posted - 3 days ago

while $SLS 009 Achieved a 100% Complete Response Rate for Optimally Dosed ASXL1+, end stage Dying AML Patients -- we see another outmoded, non selective, CDK9 bites the dust $KRON kb-0742, of the first 7 p2 patients dosed, 2 quit, 5 had neurological side affects. -- this is what a PRISTINE Phase 2 Safety profile Looks like, NO DLT's, No patient DQt, No Grade 3 or 4 Side Effects - in addition to the 77 Patient P1, that had no serious side Affects. https://ash.confex.com/ash/2024/webprogram/Paper198686.html

User Image Digital_Waffle_Pirate Posted - 3 days ago

$KRON https://x.com/PirateWaffle

User Image GPS_OS_21_vs_SOC_5 Posted - 4 days ago

$SLS $85M - 100% Complete Response in Optimally Dosed ASXL1+ END Stage Dying AML Patients. -- all 009 Needs for FDA Approval is 25%. I am thinking we will Get 4 More 009 Pr's this Quarter ... - DLBCL Genfleet Phase 2 combo Results w Zanubrutinib, - PIVOT NIH Pediatric Results, - ASH P2A Full Publication and Market Reaction, - SLS009 Phase 2B Topline in all ASXL1+ MR Setting, and Possibly PH2B ASH Late Breaker, + GPS Phase 3 REGAL Results, 5 years in the Making. - A Positive P3 Result and $SLS is Instantly worth multiple Billions, it will give Gps the FDA Green Light to Treat upwards of 25,000 AML Remission Patients Each year -a $6B TAM. $KRON $VINC $XBI

User Image GPS_OS_21_vs_SOC_5 Posted - 4 days ago

$XBI $SLS SLS009 is already worth More than a Billion - right now - the Market will be Catch ing up to Highbridge. Do some DD on Kura and Sndx Value. SLS009 Phase 2 100% CR Rates are worth a Fu_k ton more than $85M. Dr. Zeidner and Kadia were clear as a bell, all SLS009 needed to beat 25% Response Rates for FDA Approval - Its 100%. " 50% Response Rate in the Optimal dose"... Clinical was even higher in patients .. w ASXL1+ ... Combined w the PreLim data, we can determine Optimal Dosed ASXL1+ patients have a CR Rate of 100% . CR at 100% for End Stage Dying, relapsed and Refractory to Aza VEN, AML Patients. - the market will be correcting the Value Share Price imbalance. -And not 1 Grade 3 or 4 SA, $VINC would be worth 2B by now if VIP150 had these P2A Results. Same thing w $KRON 's CDK9.

User Image GPS_OS_21_vs_SOC_5 Posted - 5 days ago

$SLS $85M MCap ASH publication confirmed 100% Complete Response rates for SLS009 optimally, dosed asxl1+ AML patients, who are relapsed refractory to Aza Ven - look at $SNDX Fda approval for 21% CR in another AML subset, and 25% were Ven naive. SLS009 also has a pristine Safety Profile, the Most Selective and First Ever Safe CDK9 https://ash.confex.com/ash/2024/webprogram/Paper198686.html $kron $VINC - SLS009 100% CR Rates, No DLT's No Serious SA's https://ir.syndax.com/news-releases/news-release-details/syndax-presents-positive-data-pivotal-augment-101-trial

User Image Digital_Waffle_Pirate Posted - 6 days ago

$KRON My final post (here on ST) on Kronos until the dust is settled: Happy as a pig in shit watching the bio-bombs fall all around me. If you hold Kronos (and I'm not sure anyone does but me), you're probably in an excellent spot for the following reasons: 1. There is little to suggest in their PR or their 10Q that the company will continue or reverse merge - it's written definitively like a wind-down, and because of the situation with the equity, the S-3 that went into effect today is worthless because its baby shelf is restricted. What that means is that the equity would have to materially improve its stock price to raise the value of the public float, and over time, because the SEC calculates public float value on a semi-annual basis... they couldn't just improve temporarily in order for it to change the raisable amount from $15M to the total $250M... we're talking about getting the price up above $1.65 and keeping it there until the end of Q2 2025 - that ain't happening.

User Image anachartanalyst Posted - 1 week ago

$KRON https://anachart.com/wp-content/uploads/ana_temp/1731585691_soc-img.jpg

User Image WallStArb Posted - 1 week ago

@NotBornYesterday there is no large slug of cash. Net cash as of right now is 76,209,889 --> burn $25m +/- with wind down costs and you are still looking at $50m $KRON would need to trade 25% under that to make it worthwhile for Kevin Tang or similar and you can get a CVR

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON @telomerase ANOTHER failed cdk9 inhibitor for you 😂

User Image WallStArb Posted - 1 week ago

$KRON Based on my experience with a LARGE position in $AVRO aka $TECX they pissed through about 40% of cash from the time they announced and they were much better managed. $KRON has $40m of cash liabilities so lop that off now - then lop off $10m a qtr for 3 - 4 qtrs. so 125 - 40 - 40 = 45. So you could guesstimate $45m value left - so maybe its ok risk reward at a $30m market cap

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON Time for a reset! as only a few 🧩 remain relevant: 🧩 Company winding down 🧩 A CFO with a history of transitional work 🧩 A re-upped $250 million shelf 🧩 No news on Genentech

User Image WallStArb Posted - 1 week ago

@Digital_Waffle_Pirate KRON $1.19 a share net cash - assume it takes 9 - 12mo ($AVRO took that) AVRO $TECX had net cash $3 a share - traded @ 40% of it at the low $1.00 - $1.20 area - so if we assume similar $.50 area or lower for $KRON - i wouldn't bother with $KRON unless its $0.40 or lower - there's no value to the platform

User Image DonCorleone77 Posted - 1 week ago

$KRON Kronos Bio reports Q3 EPS (23c), consensus (28c) Reports Q3 revenue $2.37M, consensus $2.1M. "While we believe istisociclib has provided benefit to a small number of patients in the Phase 1/2 trial, the emerging profile in patients with platinum-resistant ovarian cancer suggests an unfavorable risk-benefit profile and does not warrant further clinical development," said Norbert Bischofberger, Ph.D., chief executive officer. "We are very grateful to the patients, caregivers and medical staff who dedicated their time and energy to make this clinical trial possible and your commitment to evaluating novel approaches to treat cancer."

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON So now the company agrees with me that no value should be assigned to its assets, and the status of the Genentech work is a complete black box still. $100 M+ up for grabs, and a partnership with zero updates.

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON 😂 that’s why you don’t assign value to assets that aren’t bangers! Glad they recognize the platform is the only thing worth anything. @WallStArb who comes for the $100 million? https://ir.kronosbio.com/news-releases/news-release-details/kronos-bio-reports-third-quarter-2024-financial-results-and

User Image Bondrewd Posted - 1 week ago

$KRON time too do DD

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON Genentech and Kronos continue to tread the same ground; although they have different epigenetic mechanisms, there is a shared outcome around Th17-targeted cytokine control. https://www.biorxiv.org/content/10.1101/2024.11.08.622668v1

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON Once more unto the breach, dear friends, once more; oh Norbert, my falstaff.

User Image Wrangler4 Posted - 1 week ago

$BLUE $KRON Cool !! let @RallyRaider , know ..haha

User Image WallStArb Posted - 1 week ago

@Wrangler4 $BLUE is going to zero due to issuing debt rather than equity when it was $150 a share $KRON just doesn’t have anything of value in the pipeline

User Image Wrangler4 Posted - 1 week ago

$KRON Looking spectacular, lol…another $BLUE

User Image Digital_Waffle_Pirate Posted - 1 week ago

$KRON 😂😂 re-upped offering and deficient all at once

User Image DonCorleone77 Posted - 1 week ago

$KRON Kronos Bio files $250M mixed securities shelf

User Image Tumble51 Posted - 2 weeks ago

$KRON More fallout on this joke

User Image Digital_Waffle_Pirate Posted - 2 weeks ago

$KRON ASH, methodology focused. https://ash.confex.com/ash/2024/webprogram/Paper210684.html

User Image GPS_OS_21_vs_SOC_5 Posted - 2 weeks ago

$SLS Dr. Zeidner and Kadia were clear as a bell, all SLS009 needed to beat 25% Response Rates for FDA Approval - Its 100%. " 50% Response Rate in the Optimal dose"... Clinical was even higher in patients .. w ASXL1+ ... Combined w the PreLim data, we can determine Optimal Dosed ASXL1+ patients have a CR Rate of 100% . CR at 100% for End Stage Dying, relapsed and Refractory to Aza VEN, AML Patients. - You can expect BIG PHARMA will be Fairly Valuing this asset, even though the Current Rigged Market Does not. -And not 1 Grade 3 or 4 SA, $VINC would be worth 2B by now if VIP150 had these P2A Results. Same thing w $KRON 's CDK9.

User Image Digital_Waffle_Pirate Posted - 2 weeks ago

$KRON 30 days below $1 and is now bid deficient - cue the initial 180 day clock to delisting! 👏👏👏👏👏👏👏👏👏👏

User Image Digital_Waffle_Pirate Posted - 2 weeks ago

$KRON ASH 😴😴😴

User Image Wrangler4 Posted - 10/30/24

$KRON The wind blew the mat, fake jump

Analyst Ratings
HC Wainwright & Co. Buy Aug 19, 24
HC Wainwright & Co. Buy Aug 1, 24
HC Wainwright & Co. Buy May 3, 24
Piper Sandler Overweight Dec 19, 23
HC Wainwright & Co. Buy Dec 19, 23
HC Wainwright & Co. Buy Nov 27, 23
HC Wainwright & Co. Buy Aug 21, 23
HC Wainwright & Co. Buy Apr 17, 23
HC Wainwright & Co. Buy Nov 18, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dinsmore Christopher Chief Scientific Off.. Chief Scientific Officer Jan 04 Sell 1.1836 7,366 8,718 260,969 01/05/24
DiMartino Jorge Chief Medical Office.. Chief Medical Officer & VP Jan 04 Sell 1.1836 12,009 14,214 315,246 01/05/24
Kosacz Barbara COO & General Counse.. COO & General Counsel Jan 04 Sell 1.1836 10,676 12,636 928,966 01/05/24
BISCHOFBERGER NORBERT W President & CEO President & CEO Nov 15 Buy 0.96 1,731,056 1,661,814 2,540,665 11/17/23
Dinsmore Christopher Chief Scientific Off.. Chief Scientific Officer Feb 24 Sell 1.7355 6,291 10,918 285,001 02/24/23
DiMartino Jorge Chief Medical Office.. Chief Medical Officer & VP Feb 24 Sell 1.7355 10,153 17,621 355,440 02/24/23
Al-Wakeel Yasir B. Chief Financial Offi.. Chief Financial Officer Feb 24 Sell 1.7355 9,026 15,665 355,719 02/24/23
BISCHOFBERGER NORBERT W President & CEO President & CEO May 17 Buy 3.78 597,129 2,257,148 809,609 05/19/22